As part of its global initiative to align with customers worldwide, Pall has inaugurated its newest Life Sciences Centre of Excellence in Bangalore, India
The centre will drive process optimisation innovations for the global life sciences market to meet the evolving opportunities and challenges of this fast-growing industry throughout Asia.
The new centre includes a state-of-the-art proteomics laboratory to help customers speed the drug discovery process.
It also houses a validation laboratory and a training facility with specialty experts to support Indian and regional customers as they increasingly enter the stringently regulated drug export market.
India was strategically chosen as the location for Pall's new Centre of Excellence in Asia because of the country's highly regarded reputation in life sciences spanning biopharmaceutical research, development and production.
Additionally, India's diverse market opportunities coupled with a large pool of qualified scientists and engineers provide an ideal climate for fuelling innovation and growth.
"Pall's growth in the Asian life sciences market is a reflection of our focus on this important region and our continuing commitment to undertake several customer-centric initiatives there," says Roberto Perez, president, Pall Life Sciences Worldwide.
"The new Centre of Excellence will be instrumental in helping the life sciences industry in India and throughout the region apply the latest technologies and services to their operations, so they have the optimal tools and expertise to bring new and innovative drugs to market more efficiently".
As Indian-based companies address the health care needs of their nation's billion plus population and also expand into the global marketplace, they constantly seek new approaches to broaden and improve their drug pipeline and their ability to produce them to a world-class standard.
The new centre will provide the pharmaceutical, biotechnology and discovery markets throughout the region with a full range of total fluid management solutions to help them achieve their goals.
Led by a highly specialised team of professionals, the new centre joins other Pall Life Sciences Centres of Excellence throughout Europe and the western hemisphere in bringing together the latest technologies with process optimisation knowledge and expertise.
With the opening of the centre, Pall Life Sciences also expands its customer technical support system.
Customers anywhere in the world will be able to have immediate access (24 hours, 7 days a week) to Pall scientists and technical experts.
"The success of our customers depends on their ability to carry out all stages of drug development - research, discovery and full-scale production - efficiently and cost-effectively," says Vinay Joban, general manager, Pall BioPharmaceuticals India.
"The new centre provides the region with a complete range of services to support their operations from upstream through downstream while also facilitating their ability to comply with increasingly rigorous global requirements".
The biopharmaceutical industry throughout Asia is experiencing a major surge in activity.
The Indian pharmaceutical industry is one of the world's largest, ranking 4th in terms of volume.
According to Opportunities in Indian Pharma Sector (July 2006), India holds US$6bn of the $550billion global pharmaceutical industry, an annual increase of ten percent compared with the seven percent annual growth of the overall world market.
The biotechnology market is also booming in India and is expected to continue on a fast pace with the support of the government through its comprehensive national biotechnology policy.
Indian Biotechnology Market Outlook (February 2007) reports that the Indian biotechnology industry has grown 28.09 percent from 2005, and is likely to touch the US$5bn mark by the end of 2010.
"Our new Centre of Excellence is the latest demonstration of Pall's long-term commitment to grow and invest in Asia and align with our customers worldwide," says Vinay Gupta, managing director and head of Pall Life Sciences in India.
"It is key to our global strategy of working as a partner with the pharmaceutical and biotechnology industries and the academic research community to provide them with a full range of total process management solutions for improved optimisation."
